|
|
|
Volumn 26, Issue 2, 2013, Pages 34-40
|
|
Therapeutic antibodies in review
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTIBODY DRUG CONJUGATE;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ALKALOID;
AURISTATIN;
BELIMUMAB;
BEVACIZUMAB;
BRENTUXIMAB VEDOTIN;
CAPECITABINE;
CD30 ANTIGEN;
CYTOTOXIC AGENT;
DOCETAXEL;
EMTANSINE;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
INFLIXIMAB;
IPILIMUMAB;
LAPATINIB;
MOGAMULIZUMAB;
PERTUZUMAB;
POTELIGEO;
RANIBIZUMAB;
RAXIBACUMAB;
TAXANE DERIVATIVE;
TOXIN;
TOXIN DM 1;
TRASTUZUMAB;
TRASTUZUMAB EMTANSINE;
UNCLASSIFIED DRUG;
VINCA ALKALOID;
ANTHRAX;
APOPTOSIS;
ARTICLE;
ASTHMA;
BLEEDING;
BLOOD PRESSURE;
BRAIN CANCER;
BREAST METASTASIS;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
COLON CANCER;
DIABETIC MACULAR EDEMA;
DRUG APPROVAL;
DRUG CYTOTOXICITY;
DRUG EFFICACY;
DRUG MARKETING;
DRUG POTENCY;
DRUG RECEPTOR BINDING;
DRUG SAFETY;
DRUG TISSUE LEVEL;
ENTERITIS;
HODGKIN DISEASE;
HUMAN;
IMMUNOMODULATION;
KIDNEY CANCER;
LUNG CANCER;
LUPUS VULGARIS;
MOLECULARLY TARGETED THERAPY;
NONHUMAN;
PROGRESSION FREE SURVIVAL;
RHEUMATOID ARTHRITIS;
SIDE EFFECT;
UNSPECIFIED SIDE EFFECT;
VISUAL IMPAIRMENT;
|
|
EID: 84875081192
PISSN: 1542166X
EISSN: 19391862
Source Type: Trade Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (6)
|
